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We thank Heneghan and colleagues for their interest [1] 
in our article [2].
We do not claim our article to be the ﬁ  rst evidence that 
circulating microRNAs (miRNAs) have potential as 
breast cancer biomarkers, and we acknowledge that other 
groups such as theirs are working on this exciting new 
area (for example, [3]). However, we think that our data 
on the association with breast tumor progression are 
novel.
Th  e ﬁ  nding that total RNA levels were higher in M0 
patients than in controls and M1 breast cancer patients 
cannot exclusively reﬂ  ect the quality of our used RNA 
extraction technique because the diﬀ  erence in the con-
centrations was signiﬁ  cant, and we used the same tech-
nique for all groups. When we quantiﬁ   ed the RNA 
concentrations using the mirVana PARIS kit (Ambion) 
and the Trizol® extraction (Invitrogen), we found the 
RNA amounts diﬀ   ered considerably, but the relative 
changes in the RNA levels of the diﬀ  erent groups showed 
the same tendency. Th  e fact that whole blood contains 
higher RNA amounts than serum/plasma is an un  dis-
putable matter. However, we intended to measure the 
amounts of cell-free RNA.
In our article we discussed that the lower total RNA 
levels in patients with metastatic disease compared to 
M0 patients might be explained in part by the diﬀ  erent 
tissue sources (for example, primary tumor, circulating 
tumor cells and mononuclear cells) from which the bulk 
of RNA in blood may come. Th  e claim that total RNA 
concentration indicated tumor progression alludes to the 
higher total RNA levels detected in the more advanced 
tumor stages within the M0 subgroup.
We selected our miRNA panel from a large number of 
existing miRNAs because these miRNAs target mRNAs 
crucial in breast cancer progression (for example, 
epithelial-mesenchymal transition). Certainly, there are 
other miRNAs strongly associated with breast cancer.
We agree that the pre-operative analysis of blood 
should be more informative for cancer detection, whereas 
the post-operative analysis might be more valuable to 
estimate tumor progression. Our small pilot study on 
sera from 10 patients revealed similar levels before and 
about 4 weeks after surgery (P = 0.375); however, this 
aspect needs to be revisited with a larger cohort of 
patients.
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